Phase III Study of 608 Injection for Adults With Active Ankylosing Spondylitis Evaluating Effectiveness and Safety Compared to Placebo

What this Trial Is About

Researchers are evaluating the efficacy and safety of the drug 608 in adult patients with active ankylosing spondylitis AS. The trial aims to demonstrate the clinical efficacy of 608 at week 16 compared to placebo and to assess both safety and tolerability up to week 16, with ongoing long-term safety monitoring up to week 60. This is a phase 3, randomized, double-blind, placebo-controlled study involving adults aged 18 years and older. Participants receive either 608 or a placebo through subcutaneous injections. The treatment period includes 16 weeks to evaluate primary and secondary outcomes, followed by continued observation for safety up to week 60. The study includes a placebo control group to compare responses and assess the effect of 608 on ankylosing spondylitis symptoms. During the trial, participants undergo assessments to measure their response according to the Assessment of Spondylo Arthritis International Society ASAS criteria at week 16. Safety and tolerability are also closely monitored throughout the study and the extended follow-up period. The total involvement includes periodic evaluations, laboratory tests, and clinical monitoring to ensure participant safety and to measure treatment effects over time.

A Study to Evaluate the Efficacy and Safety of 608 in Adult Subjects With Active Ankylosing Spondylitis(AS)